Mineralys Therapeutics (MLYS) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Viridian Therapeutics (VRDN) has outperformed Mineralys Therapeutics (MLYS) over the past year, losing 14.1% versus a loss of 40.3%. Viridian Therapeutics is the larger company by market cap ($2.11 billion vs $2.07 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | VRDN |
|---|---|---|
| Share price | $23.37 | $18.66 |
| Market cap | $2.07B | $2.11B |
| 1-day change | +4.42% | +1.74% |
| YTD return | -38.33% | -41.07% |
| 1-year return | -40.30% | -14.14% |
| 5-year return | — | +7.44% |
| EPS (TTM) | $-4.22 | $-3.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $70.85M |
| Revenue growth (YoY) | — | +23359.93% |
| Net income (latest FY) | $-154.65M | $-342.60M |
| Operating margin | — | -512.91% |
| Net margin | — | -483.57% |
| 52-week high | $47.65 | $34.29 |
| 52-week low | $21.46 | $13.18 |
| Distance from 52-week high | -50.95% | -45.58% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +107.53% | +96.95% |
| Average volume | 1.04M | 1.71M |
| Shares outstanding | 88.41M | 113.29M |
| Employees | 76 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VRDN has outperformed MLYS by 26.2 percentage points over the past year.
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
MLYS vs VRDN FAQ
Which is bigger, Mineralys Therapeutics or Viridian Therapeutics?
Viridian Therapeutics (VRDN) is larger, with a market capitalization of $2.11B compared with $2.07B for Mineralys Therapeutics (MLYS).
Which stock has performed better over the past year, MLYS or VRDN?
VRDN returned -14.14% over the past 12 months, compared with -40.30% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Mineralys Therapeutics and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.